-
1
-
-
61649102842
-
Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard
-
Prasaja B, Sasongko L, Harahap Y, Hardiyanti, Lusthom W, Grigg M. Simultaneous quantification of losartan and active metabolite in human plasma by liquid chromatography-tandem mass spectrometry using irbesartan as internal standard. J. Pharm. Biomed. Anal. 49(3), 862-867 (2009).
-
(2009)
J. Pharm. Biomed. Anal.
, vol.49
, Issue.3
, pp. 862-867
-
-
Prasaja, B.1
Sasongko, L.2
Harahap, Y.3
Hardiyanti4
Lusthom, W.5
Grigg, M.6
-
2
-
-
67649379367
-
Serotonergic drugs and valvular heart disease
-
Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin. Drug Saf. 8(3), 317-329 (2009).
-
(2009)
Expert Opin. Drug Saf.
, vol.8
, Issue.3
, pp. 317-329
-
-
Rothman, R.B.1
Baumann, M.H.2
-
3
-
-
0005590750
-
Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation
-
Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin. Pharmacol. Ther. 67, 275-282 (2000).
-
(2000)
Clin. Pharmacol. Ther.
, vol.67
, pp. 275-282
-
-
Manyike, P.T.1
Kharasch, E.D.2
Kalhorn, T.F.3
Slattery, J.T.4
-
4
-
-
0033012622
-
Quantification in patient urine samples of felbamate and three metabolites: Acid carbamate and two mercapturic acids
-
Thompson CD, Barthen MT, Hopper DW et al. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 40, 769-776 (1999).
-
(1999)
Epilepsia
, vol.40
, pp. 769-776
-
-
Thompson, C.D.1
Barthen, M.T.2
Hopper, D.W.3
-
5
-
-
33846424676
-
Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: A review
-
Masubuchi Y. Metabolic and non-metabolic factors determining troglitazone hepatotoxicity: a review. Drug Metab. Pharmacokinet. 21(5), 347-356 (2006).
-
(2006)
Drug Metab. Pharmacokinet.
, vol.21
, Issue.5
, pp. 347-356
-
-
Masubuchi, Y.1
-
6
-
-
66449102106
-
Studies on the chemical reactivity of diclofenax acyl glucuronide with glutathione: Identification of diclofenac-S-acyl-glutathione in rat bile
-
Grillo MP, Knutson CG, Sanders PE, Waldon DJ, Hua F, Ware JA. Studies on the chemical reactivity of diclofenax acyl glucuronide with glutathione: identification of diclofenac-S-acyl-glutathione in rat bile. Drug Metab. Dispos. 37(5), 1073-1082 (2009).
-
(2009)
Drug Metab. Dispos.
, vol.37
, Issue.5
, pp. 1073-1082
-
-
Grillo, M.P.1
Knutson, C.G.2
Sanders, P.E.3
Waldon, D.J.4
Hua, F.5
Ware, J.A.6
-
7
-
-
33845734598
-
A regulatory perspective on issues and approaches in characterizing human metabolites
-
Davis-Bruno KL, Atrakchi A. A regulatory perspective on issues and approaches in characterizing human metabolites. Chem. Res. Toxicol. 19, 151-1563 (2006).
-
(2006)
Chem. Res. Toxicol.
, vol.19
, pp. 151-1563
-
-
Davis-Bruno, K.L.1
Atrakchi, A.2
-
9
-
-
0038162231
-
Drug metabolites in safety testing
-
Hastings KL, El-Hage J, Jacobs A, Leighton J, Morse D, Osterberg RE. Drug metabolites in safety testing. Toxicol. Appl. Pharmacol. 190(1), 91-92 (2003).
-
(2003)
Toxicol. Appl. Pharmacol.
, vol.190
, Issue.1
, pp. 91-92
-
-
Hastings, K.L.1
El-Hage, J.2
Jacobs, A.3
Leighton, J.4
Morse, D.5
Osterberg, R.E.6
-
10
-
-
0020409221
-
Determination of formaldehyde in biological tissues by gas chromatography/mass spectrometry
-
Heck HD, White EL, Casanova-Schmitz M. Determination of formaldehyde in biological tissues by gas chromatography/mass spectrometry. Biomed. Mass Spectrom. 9, 347-353 (1982).
-
(1982)
Biomed. Mass Spectrom.
, vol.9
, pp. 347-353
-
-
Heck, H.D.1
White, E.L.2
Casanova-Schmitz, M.3
-
11
-
-
62249100639
-
Safety assessment of drug metabolites: Implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s
-
Powley MW, Frederick CB, Sistare FD, DeGeorge JJ. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s. Chem. Res. Toxicol. 22, 257-262 (2009).
-
(2009)
Chem. Res. Toxicol.
, vol.22
, pp. 257-262
-
-
Powley, M.W.1
Frederick, C.B.2
Sistare, F.D.3
Degeorge, J.J.4
-
12
-
-
33751249069
-
Complicating factors in safety testing of drug metabolites: Kinetic differences between generated and preformed metabolites
-
Preuksaritanont T, Lin JH, Baille TA. Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites. Toxicol. Appl. Pharmacol. 217, 143-152 (2006).
-
(2006)
Toxicol. Appl. Pharmacol.
, vol.217
, pp. 143-152
-
-
Preuksaritanont, T.1
Lin, J.H.2
Baille, T.A.3
-
13
-
-
59649103035
-
Safety testing of metabolites: Expectations and outcomes
-
Pang SK. Safety testing of metabolites: expectations and outcomes. Chem. Biol. Interact. 179, 45-59 (2009).
-
(2009)
Chem. Biol. Interact.
, vol.179
, pp. 45-59
-
-
Pang, S.K.1
-
14
-
-
0018121698
-
Kinetics of metabolite formation and elimination in the perfused rat liver preparation: Differences between elimination of preformed acetaminophen and acetaminophen formed from phenacetin
-
Pang KS, Gillette JR. Kinetics of metabolite formation and elimination in the perfused rat liver preparation: differences between elimination of preformed acetaminophen and acetaminophen formed from phenacetin. J. Pharmacol. Exp. Ther. 207, 178-194 (1978).
-
(1978)
J. Pharmacol. Exp. Ther.
, vol.207
, pp. 178-194
-
-
Pang, K.S.1
Gillette, J.R.2
-
15
-
-
24944563781
-
Seeing through the MIST: Abundance versus percentage. Commentary on metabolites in safety testing
-
Smith DA, Obach RS. Seeing through the MIST: abundance versus percentage. Commentary on metabolites in safety testing. Drug Metab. Dispos. 33(10), 1409-1417 (2005).
-
(2005)
Drug Metab. Dispos.
, vol.33
, Issue.10
, pp. 1409-1417
-
-
Smith, D.A.1
Obach, R.S.2
-
16
-
-
33845748169
-
Metabolites and safety: What are the concerns, and how should we address them?
-
Smith DA, Obach RS. Metabolites and safety: what are the concerns, and how should we address them? Chem. Res. Toxicol. 19, 1570-1579 (2006).
-
(2006)
Chem. Res. Toxicol.
, vol.19
, pp. 1570-1579
-
-
Smith, D.A.1
Obach, R.S.2
-
18
-
-
34447556889
-
Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation
-
Ball D, Blanchard J, Jacobson-Kram D. Development of safety qualification thresholds and their use in orally inhaled and nasal drug product evaluation. Tox. Sci. 97(2), 226-236 (2007).
-
(2007)
Tox. Sci.
, vol.97
, Issue.2
, pp. 226-236
-
-
Ball, D.1
Blanchard, J.2
Jacobson-Kram, D.3
-
19
-
-
0008934176
-
Effects of gastrointestinal disease on drug absorption
-
Benet LZ, Massoud N, Gambertoglio JG (Eds). Raven Press, NY, USA
-
Welling PG. Effects of gastrointestinal disease on drug absorption. In:Pharmacodynamic Basis for Drug Treatment . Benet LZ, Massoud N, Gambertoglio JG (Eds). Raven Press, NY, USA, 29-47 (1984).
-
(1984)
Pharmacodynamic Basis for Drug Treatment
, pp. 29-47
-
-
Welling, P.G.1
-
20
-
-
28944450056
-
Review article: Similarities and differences among delayedrelease proton pump inhibitor formulations
-
Horn JR, Howden CW. Review article: similarities and differences among delayedrelease proton pump inhibitor formulations. Aliment. Pharmacol. Ther. 22(Suppl. 3), 20-24 (2005).
-
(2005)
Aliment. Pharmacol. Ther.
, vol.22
, Issue.SUPPL. 3
, pp. 20-24
-
-
Horn, J.R.1
Howden, C.W.2
-
21
-
-
24044546760
-
Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats
-
Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG. Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats. Tox. Sci. 87(1), 277-284 (2005).
-
(2005)
Tox. Sci.
, vol.87
, Issue.1
, pp. 277-284
-
-
Robosky, L.C.1
Wells, D.F.2
Egnash, L.A.3
Manning, M.L.4
Reily, M.D.5
Robertson, D.G.6
-
22
-
-
33645805875
-
Communication regarding metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats
-
Robosky LC, Wells DF, Egnash LA, Manning ML, Reily MD, Robertson DG. Communication regarding metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl:CD[SD]) Rats. Tox. Sci. 91(1), 309 (2006).
-
(2006)
Tox. Sci.
, vol.91
, Issue.1
, pp. 309
-
-
Robosky, L.C.1
Wells, D.F.2
Egnash, L.A.3
Manning, M.L.4
Reily, M.D.5
Robertson, D.G.6
-
23
-
-
67650595188
-
The role of gut microbiota in drug response
-
Wilson ID, Nicholson JK. The role of gut microbiota in drug response. Curr. Pharm. Des. 15(13), 1519-1523 (2009).
-
(2009)
Curr. Pharm. Des.
, vol.15
, Issue.13
, pp. 1519-1523
-
-
Wilson, I.D.1
Nicholson, J.K.2
-
24
-
-
0032589627
-
Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: Species differences in the metabolism of efavirenz
-
Mutlib AE, Chen H, Nemeth GA et al. Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab. Dispos. 27, 1319-1333 (1999).
-
(1999)
Drug Metab. Dispos.
, vol.27
, pp. 1319-1333
-
-
Mutlib, A.E.1
Chen, H.2
Nemeth, G.A.3
-
25
-
-
84906677767
-
-
Guidance for industry S1C(R2) dose selection for carcinogenicity studies
-
Guidance for industry (2008) S1C(R2) dose selection for carcinogenicity studies www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/ guidances/ucm074919.pdf
-
(2008)
-
-
-
26
-
-
84906668842
-
Draft guidance for industry on safety testing of drug metabolites
-
Draft guidance for industry on safety testing of drug metabolites, Federal Register, 70(107), 32839 (2005) http://0-edocket.access.gpo.gov.library. colby. edu/2005/pdf/05-11205.pdf
-
(2005)
Federal Register
, vol.70
, Issue.107
, pp. 32839
-
-
-
28
-
-
0004592386
-
-
US Environmental Protection Agency. OPPTS 870.7485. Metabolism and pharmacokinetics
-
US Environmental Protection Agency (1998). Health effects test guidelines. OPPTS 870.7485. Metabolism and pharmacokinetics www.epa.gov/ opptsfrs/publications/oppts-harmonized/870-health-effects-test-guidelines/ series/870-7485.pdf
-
(1998)
Health Effects Test Guidelines
-
-
-
29
-
-
84906711200
-
-
Guidance for Industry on Safety Testing of Drug Metabolites
-
Guidance for Industry on Safety Testing of Drug Metabolites (2008) www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm079266.pdf
-
(2008)
-
-
-
30
-
-
84906711199
-
-
NTP TR 289, Toxicology and carcinogenesis studies of benzene (CAS No. 71-43-42) in F344/N rats and B6C3F1 mice
-
NTP TR 289. Toxicology and carcinogenesis studies of benzene (CAS No. 71-43-42) in F344/N rats and B6C3F1 mice (1986) http://ntp.niehs.nih.gov/ntp/ htdocs/LT-rpts/tr289.pdf
-
(1986)
-
-
-
32
-
-
84906694356
-
-
Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (step 5 finalized ICH guideline)
-
Guideline on nonclinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals (step 5 finalized ICH guideline) www.ich.org/lob/media/media5544.pdf
-
-
-
-
33
-
-
84906711196
-
-
Guideline for industry toxicokinetics: the assessment of systemic exposure in toxicity studies (ICH 3A) March
-
Guideline for industry toxicokinetics: the assessment of systemic exposure in toxicity studies (ICH 3A, March 1995) www.fda.gov/downloads/drugs/ guidancecomplianceregulatoryinformation/guidances/ucm074937.pdf
-
(1995)
-
-
-
34
-
-
84906711197
-
-
Guidance for industry genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft guidance December)
-
Guidance for industry genotoxic and carcinogenic impurities in drug substances and products: recommended approaches (draft guidance, December 2008) www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ ucm079235.pdf
-
(2008)
-
-
|